Advertisement

Topics

Ivosidenib Holds Greatest Benefit for Older Patients With IDH1-Mutant AML

13:57 EDT 16 Apr 2019 | OncLive

Courtney D. DiNardo, MD, MSCE, discusses the findings of the phase I dose-escalating study that led to the initial approval of ivosidenib for adult patients with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.

Original Article: Ivosidenib Holds Greatest Benefit for Older Patients With IDH1-Mutant AML

NEXT ARTICLE

More From BioPortfolio on "Ivosidenib Holds Greatest Benefit for Older Patients With IDH1-Mutant AML"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...